IBJNews

Lilly, Boehringer submit diabetes drug to FDA

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.

Lilly said the treatment, a once-daily tablet named empagliflozin, belongs to a class of drugs that aim to reduce blood sugar levels in patients by blocking glucose reabsorption in the kidney and removing excess glucose through urine. The drug does not depend on a patient's insulin levels to be effective, unlike other treatments.

Type 2 is the most common form of diabetes, a chronic disease in which a person's body doesn't properly produce or use the hormone insulin.

Lilly said in January that empagliflozin proved more effective than a placebo in initial results from several late-stage studies. The Indianapolis-based company will present more details on the studies at the American Diabetes Association annual meeting in June.

A Lilly spokeswoman declined to say when the FDA expects to make its decision on whether to approve the drug.

Lilly and Boehringer started teaming up in 2011 to design and sell several diabetes treatments.

Lilly shares fell 26 cents, to $55.31 each, in afternoon trading after hitting a 52-week high of $55.79 earlier in the session.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT